UroGen Pharma Ltd.
Moat Score — UroGen Pharma Ltd.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | UroGen's RTGel reverse-thermal hydrogel platform is patent-protected IP that has twice turned an off-patent generic chemotherapy (mitomycin) into an FDA-approved, differentiated product (JELMYTO and ZUSDURI), a genuinely hard-to-replicate formulation moat even though the underlying drug itself is not novel. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | UroGen has no manufacturing or scale cost advantage; its FY2024 SG&A of $121.2 million exceeded total revenue of $90.4 million, reflecting the high fixed cost of building specialty commercial infrastructure from scratch rather than any cost edge over rivals. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the only approved, non-surgical option in several of its target indications, UroGen has been able to command specialty-pharma pricing on JELMYTO and now ZUSDURI, though this power is bounded by payer reimbursement negotiations and will be tested as J&J's TAR-200 and other rivals gain approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | UroGen's products are administered directly by urologists to individual patients with no network dynamic; one patient's or physician's use does not increase the product's value to another. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | An established urology prescriber base, specialty pharmacy logistics, and payer reimbursement pathways already built around JELMYTO create some switching friction and support cross-sell of ZUSDURI to the same physicians, but newly-approved competing therapies can still displace UroGen as standard protocols evolve. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Low-grade UTUC and NMIBC were niche indications too small to attract major pharma competition for years, but that protection is eroding quickly as Johnson & Johnson, CG Oncology, and others now enter the same bladder-cancer treatment space. |